Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05069688
Other study ID # 2021P002401
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 7, 2023
Est. completion date March 31, 2025

Study information

Verified date July 2023
Source Brigham and Women's Hospital
Contact Holly Rawizza, MD, MPH
Phone 617-432-4686
Email hrawizza@bwh.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tuberculosis (TB) is the leading cause of death among children with HIV, yet insufficient data are available on the pharmacokinetics of newer HIV/TB cotreatment strategies in children. Current WHO-recommended rifampicin dosages result in low concentrations in most children, and high-dose rifampicin may improve outcomes and shorten treatment duration. Yet the impact of high-dose rifampicin on dolutegravir exposures has not been examined in children. This study aims to evaluate the safety and pharmacokinetics of dolutegravir twice daily among HIV/TB coinfected children receiving standard-dose and high-dose rifampicin.


Description:

This study is a prospective, single-arm, open-label, intensive and sparse pharmacokinetic (PK) and safety study to evaluate steady-state dolutegravir (DTG) concentrations among 20 HIV/TB coinfected children 4 weeks to <6 years of age requiring concurrent TB treatment. Ten patients will be recruited into each of two age cohorts: 4 weeks to <2 years and ≥2 years to <6 years. Children will be recruited from two large pediatric HIV clinics in Nigeria. Children in this study will receive HIV/TB cotreatment that is considered standard of care consisting of DTG twice daily during rifampicin (RIF)-containing TB treatment. For this portion of the study, the primary intervention is additional blood sampling for drug concentration determination and biomarker assessment. Additionally, during a two week period (study weeks 20-21), the RIF dose will be increased from standard-dose to high-dose RIF, during which two-way PK and toxicity monitoring will occur. Clinical and laboratory monitoring for toxicity during HIV/TB cotreatment is consistent with routine care. PK sampling for drug concentration determination will occur at three time points during the 48-week study. Specifically, PK sampling will occur at week-20 to evaluate DTG twice daily during standard-dose RIF, week-22 to evaluate DTG twice daily during high-dose RIF, and at week-30 to evaluate DTG once daily after TB treatment is complete. Additionally, the endogenous biomarker of CYP3A4 activity, 4-beta-hydroxycholesterol to cholesterol ratio, will be evaluated to advance understanding of underlying mechanisms of drug action. Blood sampling to quantify this biomarker will occur at either 4 (among ART-experienced children) or 5 (ART-naive) time points during the 48-week study.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 4 Weeks to 5 Years
Eligibility Inclusion Criteria: - ART-naïve or ART-experienced HIV-infected children between 4 weeks and <6 years of age - Active TB diagnosis - Weight of at least 3 kilograms - Consent of the parent or legal guardian Exclusion Criteria: - Baseline labs with evidence of =grade 3 abnormalities: ALT, total bilirubin, absolute neutrophil count (ANC), platelets, or creatinine - Suspected TB meningitis or presenting with acute respiratory distress or decompensation - Receipt of a medication that has drug-drug interactions with dolutegravir or rifampicin

Study Design


Intervention

Drug:
rifampicin
Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety

Locations

Country Name City State
Nigeria University College Hospital/ University of Ibadan Ibadan Oyo State

Sponsors (3)

Lead Sponsor Collaborator
Brigham and Women's Hospital APIN Public Health Initiatives, University of Cape Town

Country where clinical trial is conducted

Nigeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dolutegravir AUC during standard-dose rifampicin Dolutegravir area under the concentration time curve (AUC) will be compared to therapeutic ranges established in the adult and pediatric literature week 20
Primary Dolutegravir AUC during high-dose rifampicin Dolutegravir AUC will be compared against therapeutic ranges established in the literature and during standard-dose rifampicin week 22
Secondary Rifampicin maximum concentration (Cmax) during standard-dose rifampicin Rifampicin Cmax will be determined during standard rifampicin week 20
Secondary Rifampicin Cmax during high-dose rifampicin Rifampicin Cmax will be determined during high-dose rifampicin and compared to that observed during standard-dose rifampicin week 22
Secondary Proportion of participants experiencing severe (grade 3 or 4) clinical or laboratory adverse events Laboratory and clinical toxicities are monitored at 8 time points throughout the study and the proportion of children experiencing severe adverse events will be determined Week 48
See also
  Status Clinical Trial Phase
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Completed NCT04545164 - Computer Aided Screening for Tuberculosis in Low Resource Environments N/A
Recruiting NCT05766267 - Short-course Regimens for the Treatment of Pulmonary Tuberculosis Phase 2/Phase 3
Recruiting NCT05756582 - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Enrolling by invitation NCT04988984 - Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
Recruiting NCT04148053 - Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Recruiting NCT01689831 - Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) Phase 2
Completed NCT05945498 - Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years Phase 1
Not yet recruiting NCT06352970 - Effects of Tuberculosis Infection on Development and Function of the Placenta
Recruiting NCT04575519 - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Phase 2
Recruiting NCT05413551 - Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention Phase 1
Recruiting NCT03941210 - Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
Completed NCT04494516 - Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
Withdrawn NCT03265977 - A Phase II Study of H56:IC31 in Healthy Adolescents Phase 2
Suspended NCT05330884 - BCG Revaccination in Children and Adolescents Phase 3
Recruiting NCT05342064 - Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service N/A
Recruiting NCT05236452 - Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection N/A
Recruiting NCT05443178 - Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy Phase 1
Recruiting NCT05122026 - Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Phase 1/Phase 2
Recruiting NCT06221488 - Testing Health Workers At Risk to Advance Our Understanding of TB Infection